Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Former leaders of CDRH want to take the thinking behind the device center's TAP program into the venture capital world. Longtime center director Jeff Shuren is joining former CDRH Chief Scientist Douglas Kelly and others to launch White Oak 66 Capital, seeking to combine medtech investing with a heavy focus on helping firms proactively address reimbursement and other post-FDA commercialization risks.
In this month's news, mixed results for clinical trials, Merit Medical continues its buying streak with View Point Medical, six FDA clearances, and more.
User fees would bankroll more than half of the FDA’s FY2027 budget request. Excerpted from Pathways’ Picks April 7: Shuren Venture Fund, MDUFA Agreement, Global Digital Health Updates.